Sanofi to advance Kymera's KT-485 IRAK4 degrader; $20M milestone achieved

Kymera Therapeutics, Inc.

Sanofi selects KT-485 for Phase 1 testing in immuno-inflammatory diseases, expected to start next year; KT-474 will not advance.
KT-485 showed improved potency, selectivity, and safety profile vs KT-474 in preclinical testing.
Kymera earned a $20M milestone in Q2 2025 for preclinical activities on KT-485.
Kymera eligible for up to $975M in milestones plus double-digit royalties; may opt-in to 50/50 U.S. profit share.
Sanofi exercised participation election right for IRAK4 target under collaboration agreement.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.